Navigation
banner

European Pharma Summit

2017-11-182017-10-162017-09-16
Register 3 for the price of 2 with the coupon code rcdvb!


PLENARY KEYNOTE SPEAKERS
Sir Tom Blundell

Sir Tom Blundell
Professor Emeritus, Biochemistry & Director of Research
University of Cambridge
Sir Tom Blundell
Professor Emeritus, Biochemistry & Director of Research
University of Cambridge
 
About Speaker:

Tom Blundell maintains an active laboratory as Director of Research and Professor Emeritus in Biochemistry, University of Cambridge, where he was previously Sir William Dunn Professor and Head of Department (1996 - 2009) and Chair School of Biological Sciences (2003 - 2009). He previously held teaching and research positions in the Universities of London, Sussex and Oxford. Tom researches on molecular, structural and computational biology of growth factors, receptor activation, signal transduction and DNA repair, important in cancer, tuberculosis and familial diseases. He has described complex assemblies of FGFR and Met receptor systems necessary for high signal to noise in cell signalling, and of DNA double-strand-break repair, both NHEJ including DNA-PK and HR (Rad51 and BRCA2). Tom has produced many software packages for protein modelling and design including Modeller (~9500 citations) and Fugue (~1300 citations), and for predicting effects of mutations on stability and interactions (SDM & mCSM) to understand genetic disease and drug resistance. He has published 595 research papers, including 35 in Nature and Science. Tom developed new approaches to structure-guided and fragment-based drug discovery. In 1999 he co-founded Astex Therapeutics, an oncology company that had eight drugs in clinical trials when sold in 2013 to Otsuka for $886 million, and recently has a breast cancer drug FDA approved. In the University of Cambridge he has developed structure-guided fragment-based approaches to drug discovery for difficult targets involving multiprotein systems including Met receptor and Rad51-Brca2 complexes. He has targeted mycobacterial proteins as part with Gates HIT-TB and EU-FP7 MM4TB consortia. Tom was a member of PM Margaret Thatcher’s Advisory Council on Science & Technology (1988-1990), Founding CEO of Biotechnology and Biological Sciences Research Council, 1991-1996 (Chair 2009-2015), Chairman, Royal Commission on Environment (1998-2005), Deputy Chair of Institute of Cancer Research 2008-2015 and President of UK Science Council, 2011- 2016.

Michael Hann

Michael Hann
GSK Senior Fellow & Director, Drug Design & Selection
GlaxoSmithKline
Michael Hann
GSK Senior Fellow & Director, Drug Design & Selection
GlaxoSmithKline
 
About Speaker:

Since completing his PhD in organic chemistry in 1980, Mike has worked in Pharma R&D initially as a medicinal chemist and then as a computational chemist. He joined Glaxo in 1986 and was responsible for helping initially build and then lead the UK computational chemistry department. More recently he led the biophysics and protein crystallography activities including developing fragments theory and practice in lead identification. His current role is in looking at new ways to enhance our discovery approaches, reducing attrition and promoting scientific excellence across the GSK R&D sites. A particular current interest is in understanding drug distribution at cellular and subcellular resolution. Mike is a GSK Senior Fellow and an Adjunct Professor in the chemistry department at Imperial College London.

PLENARY SPEAKERS
Margaret Frame

Margaret Frame
Scientific Director, Cancer Research UK Edinburgh Centre
The University of Edinburgh
Margaret Frame
Scientific Director, Cancer Research UK Edinburgh Centre
The University of Edinburgh
 
About Speaker:

Margaret Frame is a research scientist with interests in novel cancer mechanisms, as evidenced by deep biology, imaging and new approaches to drug discovery and cancer therapeutics – work that has been funded by five successive CRUK (or predecessor charity) Programme grants and more recently also by an ERC Advanced Investigator Grant. From 2002-2007, Margaret was Deputy Director of the core funded CRUK Beatson Institute for Cancer Research in Glasgow, after which she moved to the University of Edinburgh (UoE). Currently she is Professor of Cancer Research, co-director of the CRUK Edinburgh Centre and Director of the MRC-Institute of Genetics and Molecular Medicine (IGMM). Margaret is very active in supporting the scientific careers of early- and mid-stage researchers, both clinical and non-clinical, an interest that stems from her time as Chairman of the CRUK New Investigator Panel and from her own experiences when building a research career during the ‘young family’ years. As Director of the IGMM, Margaret also intends to promote a strong translational agenda with innovative twists, including new approaches to biology-led drug discovery and translation of genomics to the NHS. In regard of personal achievements, Margaret was awarded the Tenovus Medal in 1999, and was elected a Fellow of the Royal Society of Edinburgh in 2002, an EMBO Member in 2007 and a Fellow of the Academy of Medical Sciences in 2009. Very recently, she was delighted to be awarded the Chancellor’s prize for Research - presented by HRH The Princess Royal (the Chancellor of the University of Edinburgh). In January 2016, she took up the role as President of the British Association for Cancer Research.

Neil McDonald

Neil McDonald
Group Leader, Signalling and Structural Biology
Francis Crick Institute
Neil McDonald
Group Leader, Signalling and Structural Biology
Francis Crick Institute
 
About Speaker:

Neil joined the Cancer Research UK London Research Institute as an independent group leader in 1994. He previously carried out postdoctoral research at Columbia University. He moved in 2016 to the new Francis Crick Institute as a Senior Scientist and has also held a chair at Birkbeck College since 2006. His research interests are focused on molecular mechanisms that control the assembly and activation of growth factor signaling complexes and their associated catalytic functions. He has contributed to several CR-UK and Wellcome Trust-funded drug discovery programs, including one that has delivered a first-in-class, pre-clinical candidate against a known cancer target. 

Julen Oyarzabal

Julen Oyarzabal
Director, Molecular Therapeutics Program
Center for Applied Medical Research (CIMA), University of Navarra
Julen Oyarzabal
Director, Molecular Therapeutics Program
Center for Applied Medical Research (CIMA), University of Navarra
 
About Speaker:

Dr. Julen Oyarzabal obtained his Ph.D. in Pharmaceutical and Organic Chemistry from University of Basque Country in 1998. After his Ph.D., he moved to the University of California San Francisco (USA); and later, he joined the University of Southampton (UK) where he worked in computational chemistry. In November 2001 he joined Johnson & Johnson Pharmaceutical R&D where he led several projects, from molecular design and chemoinformatics perspective, in the CNS therapeutic area. In October 2006, after leaving J&J, he joined the Spanish National Cancer Research Centre (CNIO) where he set up and led the Computational Medicinal Chemistry and Chemoinformatics Section. After 4 years, in September 2010 he left CNIO and joined the Center for Applied Medical Research (CIMA), at the University of Navarra, to set up the small molecule discovery platform and led the Molecular Therapeutics Program. The Program, in close interaction with the University Hospital, is running a comprehensive strategy focused on derisking drug discovery: from drug discovery informatics, biochemistry and bioanalysis to chemical biology and medicinal chemistry. As molecular tools, the Program utilizes different types of chemical probes: macrocyclic peptides, aptamers and small molecules. To date, Dr. Oyarzabal has published more than 65 research papers (e.g. Nature Comm, Angew Chem Int, Neuropsychopharmacology, J Med Chem, … as PI or co-PI). He is also co-inventor of 24 published PCT patent applications. Dr. Oyarzabal is Director of Translational Sciences of the CIMA, on the Board of Directors for the Academic Drug Discovery Consortium (ADDC), and a member of the European Medicines Agency (EMA) experts panel.

Sharad Verma

Sharad Verma
Assistant Professor, Neurology
Johns Hopkins University School of Medicine
Sharad Verma
Assistant Professor, Neurology
Johns Hopkins University School of Medicine
 
About Speaker:

Sharad K. Verma received his BS from the University of California, San Diego, PhD in Chemistry from the University of California, Irvine (Advisor : Emeritus Professor Harold Moore), and was an NIH Postdoctoral fellow at the University of California, Berkeley (Mentor : Emeritus Professor Henry Rapoport). Following completion of training in synthetic organic chemistry focused on small molecule synthesis and medicinal chemistry, he was in the pharmaceutical industry for nearly 15 years serving in various R&D roles in the discovery and clinical development of oncology therapeutics spanning the areas of signal transduction, cancer epigenetics, and immuno-oncology. While in pharma, he led the chemical identification of the first reported on-target small molecule inhibitors of the epigenetic target EZH2, and was a part of teams which delivered a total of 6 clinical development candidates (including one that is now FDA approved). Currently, he is Director of R&D for the Neurofibromatosis Therapy Acceleration Program (NTAP) and an Assistant Professor at The Johns Hopkins University School of Medicine, where he oversees basic science and translational initiatives as they pertain to the discovery and development of therapeutics for the treatment of plexiform and cutaneous neurofibromas. Additional professional activities include serving as a reviewer for various scientific journals, advisor for scientific conferences, and as a reviewer on NIH study section panels for Drug Discovery for the Nervous system, and Chemical Molecular Probes.

Drug Design & Medicinal Chemistry
DISTINGUISHED SPEAKERS
Frank Boeckler

Frank Boeckler
Professor, Pharmacy and Biochemistry
Eberhard Karls Universität Tübingen
Frank Boeckler
Professor, Pharmacy and Biochemistry
Eberhard Karls Universität Tübingen
 
About Speaker:

Frank M. Boeckler received his Ph.D. in Medicinal Chemistry at the University of Erlangen (Germany) in 2004 under supervision of Prof. Peter Gmeiner. He specialized in computational chemistry and drug design, ranging from QM methods to in silico screening. In 2006, he joined Prof. Sir Alan R. Fersht at the MRC Center for Protein Engineering in Cambridge/UK as Marie Curie fellow and discovered there p53 mutant stabilizers as potential new cancer therapeutics. While working in Cambridge at the interface of experiment and theory, he focused on molecular biology and biophysics. In 2008, he was appointed as Professor (W2tt) for Bioanalytics at Ludwig-Maximilians University (LMU) Munich. In 2010, he moved to Eberhard Karls University Tuebingen as Professor for Medicinal Chemistry/Drug Design. He is head of the laboratory of Molecular Design & Pharmaceutical Biophysics, which combines chemical biology, molecular and structural biology and biophysics, as well as computational chemistry and molecular design. His work is dedicated to understanding molecular interactions as the foundation for chemical biology and drug discovery, to apply theoretical and biophysical methods to cancer research, and to develop novel peptide-based toolkits. Since 2014, he is also member of the Center of Bioinformatics (ZBIT) of the University of Tuebingen. In 2015 he has joined the team of editors of the RÖMPP Encyclopedia covering the area of Pharmacy and Medicine. He has received multiple awards, including the Klaus-Grohe prize in Medicinal Chemistry, as well as the European Federation of Medicinal Chemistry (EFMC) Young Medicinal Chemist in Academia Prize (2016).

Andreas Brunschweiger

Andreas Brunschweiger
Research Group Leader, Chemistry & Chemical Biology
TU Dortmund
Andreas Brunschweiger
Research Group Leader, Chemistry & Chemical Biology
TU Dortmund
 
About Speaker:

Andreas Brunschweiger studied pharmacy at the University of Kiel (Germany), and joined the group of Prof. Christa Müller at the University of Bonn (Germany) to obtain his Ph.D. After conducting postdoctoral research in the same group in a collaboration project with UCB Pharma to develop small molecule inhibitors for targets associated with neurodegenerative diseases, he joined Prof. Jonathan Hall's research group at the Institute of Pharmaceutical Sciences of the ETH Zurich (Switzerland) in 2010. There, he was involved in the the development of a chemical biology strategy to identify target RNAs of microRNAs, and the design and synthesis of oligonucleotides as microRNA inhibitors. In 2013 he took up his present position as a group leader at the Faculty of Chemistry and Chemical Biology at the TU Dortmund University. His current research interests include the development of new synthesis and encoding strategies that allow for expanding the chemical space of DNA-encoded small molecule screening libraries.

Giorgio Colombo

Giorgio Colombo
Principal Investigator
Istituto di Chimica del Riconoscimento Molecolare, CNR
Giorgio Colombo
Principal Investigator
Istituto di Chimica del Riconoscimento Molecolare, CNR
 
About Speaker:

Giorgio Colombo (born 24th June 1971) received his M.Sc. Degree in chemistry in the academic year 1994/1995 from the University of Milano, Final Grade 110/110. After that, he continued his studies obtaining a Ph.D. in chemical sciences from the University of Milano in 2000. During the Ph.D period he spent one year as a visiting scientist in the laboratory of Prof. Ken Merz at the Pennsylvania State University, working on computational and theoretical approaches to study enzymatic and protein properties. He then moved to the University of Groningen as a postdoctoral fellow to work on the molecular dynamics simulations of the folding and stability of proteins and peptides. Dr. Giorgio Colombo joined the Institute for Molecular Recognition Chemistry, Italian National Research Council, in 2001 where he is currently head of the biocomputing group. In 2017, he has been appointed as a Full Professor of Organic Chemistry at the University of Pavia. He is author or coauthor of more than 150 scientific publications, all on international journals.

Jérôme Govin

Jérôme Govin
Independent Team Leader, Biosciences and Biotechnology Institute of Grenoble
University Grenoble Alpes
Jérôme Govin
Independent Team Leader, Biosciences and Biotechnology Institute of Grenoble
University Grenoble Alpes
 
About Speaker:

Dr Govin has been deciphering chromatin signaling pathways in various physiological and pathological contexts. Using model organisms, his work has been revealing molecular mechanisms and inspiring new translational approaches in biomedical research.

Ingo Hartung

Ingo Hartung
Director, Drug Discovery, Medicinal Chemistry Berlin
Bayer AG
Ingo Hartung
Director, Drug Discovery, Medicinal Chemistry Berlin
Bayer AG
 
About Speaker:

Dr. Ingo Hartung is director for medicinal chemistry at Bayer AG in Berlin and in this role responsible for Bayer’s early research portfolio in the field of immunooncology. Prior to this he lead Bayer’s activities in developing epigenetic probes in collaboration with the Structural Genomics Consortium. Dr. Hartung joined Bayer (via Schering AG) in 2004 and led optimization projects both in oncology as well as in cardiology. From 2011 to 2015 Dr. Hartung was head of microbiological chemistry at Bayer Healthcare AG. His research interests cover the field of oncology drug discovery, innovation in medicinal chemistry and the use of biocatalysis in life sciences. Dr. Hartung studied chemistry at University of Hannover/Germany and Stanford University/USA and was a postdoctoral fellow in biochemistry at Stanford University. He is a lecturer for medicinal chemistry at the Technical University Berlin/Germany and member of the American Association for Cancer Research (AACR) and the Gesellschaft Deutscher Chemiker (GDCh).

Anna Hirsch

Anna K. H. Hirsch
Professor, Drug Design and Optimization
Helmholtz Institute for Pharmaceutical Research Saarland
Anna K. H. Hirsch
Professor, Drug Design and Optimization
Helmholtz Institute for Pharmaceutical Research Saarland
 
About Speaker:

Anna Hirsch read Natural Sciences with a focus on Chemistry at the University of Cambridge and spent her third year at the Massachusetts Institute of Technology, doing a research project with Prof. Timothy Jamison on the total synthesis of amphidinolide T1.

For her Master’s project, she returned to Cambridge to develop the double conjugate addition of dithiols to propargylic carbonyl systems reaction in the group of Prof. Steven V. Ley.

She received her Ph.D. from the ETH Zurich in 2008. Her research was carried out in the group of Prof. François Diederich and consisted of de novo structure-based design and the synthesis of the first inhibitors for an enzyme as a novel approach to treat malaria.

Subsequently, she joined the group of Prof. Jean-Marie Lehn at the Institut de Science et d’Ingénierie Supramoléculaires (ISIS) in Strasbourg, before taking up a position as assistant professor at the Stratingh Institute for Chemistry at the University of Groningen in 2010. In 2015, she was promoted to associate professor of structure-based drug design. 

In 2017, she moved to the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), where she heads the department for drug design and optimization. Her work focuses on rational approaches to drug design (with a strong focus on anti-infective targets), including structure- and fragment-based drug design in combination with dynamic combinatorial chemistry and kinetic target-guided synthesis. 

Anna Hirsch was awarded the Gratama Science Prize in 2014, the SCT-Servier Prize for Medicinal Chemistry in 2015 and the Innovation Prize for Medicinal Chemistry of the GdCh/DPhG in 2017. 

György Keserű

György Keserű
Principal Investigator, Medicinal Chemistry
Hungarian Academy of Sciences
György Keserű
Principal Investigator, Medicinal Chemistry
Hungarian Academy of Sciences
 
About Speaker:

György M. Keserű obtained his Ph.D. at Budapest, Hungary and joined Sanofi-Aventis CHINOIN heading a chemistry research lab. He moved to Gedeon Richter in 1999 as the Head of Computer-aided Drug Discovery. He earned D.Sc. from the Hungarian Academy of Science in 2003 and he was invited for a research professorship at the Budapest University of Technology and Economics. Since 2007 he was appointed as the Head of Discovery Chemistry at Gedeon Richter. He served as a director general of the Research Centre for Natural Sciences (RCNS) at the Hungarian Academy of Sciences. He contributed to the discovery of the antipsychotic Vraylar® (cariprazine) that has been approved by the US FDA in 2015 and marketed in the US from 2016. From 2015 he is heading the Medicinal Chemistry Research Group at RCNS. His research interests include medicinal chemistry, drug design, and in silico ADME. He has published over 200 papers and more than 10 books and book chapters.

Steven Knight

Steven Knight
Scientific Leader, Cancer Epigenetics Discovery Performance Unit
GSK
Steven Knight
Scientific Leader, Cancer Epigenetics Discovery Performance Unit
GSK
 
About Speaker:

Dr. Steven Knight is a Scientific Leader at GlaxoSmithKline. His career has spanned over 21 years at GSK, where he has led multiple program teams to deliver clinical candidates, including inhibitors of the PI3K pathway and mitotic kinesins. Dr. Knight received a B.S. in chemistry from the University of California, Berkeley, a Ph.D. from the University of California, Irvine, and did postdoctoral studies as a NIH fellow at the University of Pennsylvania.

Karim Malik

Karim Malik
Reader & Associate Professor, Epigenetics, School of Cellular & Molecular Medicine
University of Bristol
Karim Malik
Reader & Associate Professor, Epigenetics, School of Cellular & Molecular Medicine
University of Bristol
 
About Speaker:

Currently, I am a Reader/Associate Professor in Epigenetics, School of Cellular & Molecular Medicine, University of Bristol. My main area of research is paediatric solid tumours, especially neuroblastoma and Wilms’ tumour. My interests include is histone methyltransferases as potential drug targets and signaling pathways in neuroblastoma. Our work is currently funded by Cancer Research UK, Neuroblastoma UK – Smile with Siddy, the Childrens Cancer and Leukaemia Group and the Biotechnology and Biological Sciences Research Council (BBSRC).

Michael A. Mancini

Michael A. Mancini
Professor, Molecular and Cellular Biology
Baylor College of Medicine
Michael A. Mancini
Professor, Molecular and Cellular Biology
Baylor College of Medicine
 
About Speaker:

The Mancini lab focuses upon single cell analysis of steroid receptor functions, primarily estrogen and androgen receptors (ER, AR), and attendant coregulators. Our HCA/HCS-based projects explore cell signaling, endocrine disrupting chemicals and epigenetics at the single cell level in engineered and native cultured cells.

Ingo Mugge

Ingo Mugge
Senior Research Fellow
Alkermes
Ingo Mugge
Senior Research Fellow
Alkermes
 
About Speaker:

Dr. Ingo Mügge is a Senior Research Fellow at Alkermes, Inc. In this role he leads the Modeling & Informatics efforts in the Discovery department contributing to the advancement of early drug discovery projects. Dr. Mügge has more than 20 years of experience working in the pharmaceutical industry in leadership positions at Bayer Healthcare, Boehringer Ingelheim, and Alkermes focusing on research in CNS, immunology, and cardio-metabolic related diseases. His research interests include in silico driven drug design techniques such as virtual screening, structure-based drug design, and predictive modeling. He has published more than 60 scientific papers and book chapters, co-organized scientific conferences, and serves on the scientific advisory board of Molecular Informatics. Dr. Mügge holds a European diploma degree in physics from the Humboldt University Berlin and a doctorate degree in computational chemistry from the Free University Berlin. Postdoctoral appointments allowed him to work with Yvonne Martin at Abbott Laboratories and Arieh Warshel at the University of Southern California.

Matthias Rarey

Matthias Rarey
Professor, ZBH Center for Bioinformatics
Universität Hamburg
Matthias Rarey
Professor, ZBH Center for Bioinformatics
Universität Hamburg
 
About Speaker:

Prof. Dr. Matthias Rarey heads the Center for Bioinformatics at the University of Hamburg, Germany.His background is in Computer Science (M.Sc. Paderborn, 1992, Ph.D. Bonn, 1996) with a focus on Bio- and Cheminformatics. Until July 2002, he was group leader for Cheminformatics at the Fraunhofer Institute for Algorithms and Scientific Computing (SCAI, former part of GMD). In 1997 and 2000, Prof. Rarey performed research in the cheminformatics departments of SmithKline Beecham (King of Prussia, PA) and Roche Bioscience (Palo Alto, CA). Prof. Rarey is a co-founder of the cheminformatics company BioSolveIT GmbH located in Sankt Augustin. Since 2002, he heads the Center for Bioinformatics at the University of Hamburg. He is the director of the Research Group for Computational Molecular Design which focuses on the development of new algorithms for problems occurring in molecular design, innovative approaches to cheminformatics and new molecular visualization techniques. Since 1993, Prof. Dr. Matthias Rarey has been developing innovative Software tools for structure- and ligand-based molecular design, several of which have gained international recognition, e.g. FlexX, Features Trees, PoseView, SMARTSeditor, Mona, ProToss and HYDE.

Since 2014, Prof. Rarey is an Associate Editor of the Journal of Chemical Information and Modeling of the American Chemical Society. Furthermore, he is a member in the scientific committees of Wire Computational Molecular Science and the Journal of Molecular Graphics and Modelling as well as several national and international conferences program committees. He is the spokesman of the Fachgruppe Bioinformatik (FaBI), a joint working group founded in 2014 by the Gesellschaft für Informatik e.V., the Dechema e.V., the Gesellschaft für Biochemie und Molekularchemie and the Gesellschaft Deutscher Chemiker (GDCh).

Together with his colleagues, Prof. Rarey established the study programs M.Sc. Bioinformatik and B.Sc. Computing in Science and is a member of their examinations boards as well as the responsible for the study program M.Sc. Bioinformatik. Prof. Rarey is a member of the faculty council of the Faculty of Mathematics, Informatics and Natural Sciences, he heads the PhD committee of the Faculty of Informatics. He is a liaison professor for the Studienstiftung des deutschen Volkes.

Sereina Riniker

Sereina Riniker
Professor, Physical Chemistry
ETH Zurich
Sereina Riniker
Professor, Physical Chemistry
ETH Zurich
 
About Speaker:

Sereina Riniker has been an Assistant Professor (with tenure track) of Computational Chemistry at the Laboratory of Physical Chemistry since June 2014.

She was born in Switzerland in 1985.

In 2008, she completed her master’s degree in chemistry at ETH Zurich, with a research project at the Autonomous University of Barcelona with Prof. Xavier Daura. After an internship in the research department of Givaudan AG and a research stay in the group of Prof. Berend Smit at UC Berkeley, she returned in 2009 to ETH Zurich to obtain a PhD in molecular dynamics simulations with Prof. Wilfred van Gunsteren.

From 2012 to 2014, she held a postdoctoral position in cheminformatics under the supervision of Dr. Gregory Landrum at the Novartis Institutes for BioMedical Research in Basel and Cambridge, Massachusetts.

Thomas Steinbrecher

Thomas Steinbrecher
Regional Manager, Application Science
Schrödinger
Thomas Steinbrecher
Regional Manager, Application Science
Schrödinger
 
About Speaker:

Thomas Steinbrecher studied Chemistry at the University of Freiburg in Germany and earned a diploma with distinction in Physical Chemistry. He completed a Ph.D. thesis on “Computer Simulations of Protein-Ligand Interactions” in 2005. He joined the developer team of the Amber MD package as a Postdoc at the Scripps Research Institute in San Diego and Rutgers University in New Jersey. The work focus was on efficient free energy calculation methods and QM/MM simulations of charge transfer. After returning to Germany in 2008, Thomas established a junior research group at the Karlsruhe Institute of Technology, working on fast electron transfer phenomena in DNA and proteins. He joined Schrodinger in 2013 where he is responsible for the large scale application of free energy calculation methods in pharmaceutical drug design. He currently is responsible for the European Applications Science Department.

Andrea Volkamer

Andrea Volkamer
Assistant Professor, Physiology
Charité Universitätsmedizin Berlin
Andrea Volkamer
Assistant Professor, Physiology
Charité Universitätsmedizin Berlin
 
About Speaker:

Andrea Volkamer received her Master degree in Bioinformatics from Saarland University in 2007. After a one year research stay at Purdue University (USA), she joint the group of Prof. Dr. M. Rarey at the ZBH, Hamburg. In 2013, she defended her PhD thesis with focus on computational active site and druggability predictions. After a short ProExzellezia PostDoc period, she joint BioMedX Innovation Center in Heidelberg as a PostDoc researcher, where she has been working on tools to assist the development of selective kinase inhibitors. Since July 2016, Andrea Volkamer has been an assistant professor at the Charité Berlin with the focus on structural bioinformatics and in-silico toxicicology predictions.

Gerhard Wolber

Gerhard Wolber
Professor
Freie Universität Berlin
Gerhard Wolber
Professor
Freie Universität Berlin
 
About Speaker:

Prof. Dr. Gerhard Wolber is professor for Pharmaceutical Chemistry and head of the molecular design lab at the Institute of Pharmacy at the Freie Universitaet Berlin. After his studies of pharmacy at the University of Innsbruck and Computer Science at the Technical University of Vienna, he received his PhD in pharmaceutical chemistry at the University of Innsbruck. In 2003 he co-founded the company Inte:Ligand together with partners from the University of Innsbruck, Austria. In 2008 he changed back to academia as assistant professor and group head of the Computer-Aided drug design group at the University of Innsbruck before changing to the Freie Universitaet Berlin in 2010. His research focuses on computational drug design and the development of drug development and virtual screening tools.

GPCR Targeted Screening
DISTINGUISHED SPEAKERS
Moritz Bünemann

Moritz Bünemann
Professor, Pharmacology and Clinical Pharmacy
University of Marburg
Moritz Bünemann
Professor, Pharmacology and Clinical Pharmacy
University of Marburg
 
About Speaker:

Moritz Bünemann studied biology at the University of Bochum, where he also received his Dr. rer. nat in Cellular Physiology (1996) working on GPCR desensitization and sphingolipid receptor identification and its role in signaling. He completed a postdoctoral fellowship with Marlene Hosey, Northwestern University Medical School, Chicago, USA, working on GPCR Pharmacology and Calcium channel regulation (1996-2000), He went back to start as an advanced postdoc with Martin Lohse at the University of Wuerzburg where he worked on the development of FRET-based real time assays to study GPCR function and signaling. He was promoted to a group leader and later Associate Professor for Molecular Pharmacology at University of Wuerzburg (2008-2009), In 2009 he was appointed as Professor and Chair of the Department of Pharmacology and Clinical Pharmacy, University of Marburg. Since then he worked on topics such as voltage sensitivity of GPCRs, GPCR dimerization, GPCR desensitization, GRK-Receptor interactions, GPCR-G protein recognition as well as G protein signaling in real time of various pathways.

Davide Calebiro

Davide Calebiro
Professor, Molecular Endocrinology; Principal Investigator
University of Birmingham; University of Würzburg
Davide Calebiro
Professor, Molecular Endocrinology; Principal Investigator
University of Birmingham; University of Würzburg
 
About Speaker:

Davide Calebiro is a Professor of Molecular Endocrinology at the Institute of Metabolism and Systems Research (IMSR) of Birmingham University. Prof. Calebiro studied Medicine in Milan and Stockholm and obtained a Clinical Specialization in Endocrinology and Metabolic Diseases as well as a PhD in Molecular Medicine from the University of Milan. Since 2009, he has been leading a research group at the Institute of Pharmacology and Bio-Imaging Center of Würzburg University, Germany. His group investigates the basic mechanisms of G protein-coupled receptor (GPCR) signalling and their alterations in human disease, which they elucidate using innovative biophysical techniques, such as FRET, single-molecule microscopy and various superresolution microscopy methods. His major contributions include the discovery that GPCRs are not only active at the plasma membrane but also at intracellular sites and that these receptors interact among themselves and with other membrane proteins to form dynamic nanodomains at the plasma membrane.

Niek Dekker

Niek Dekker
Principal Scientist, Discovery Biology
AstraZeneca
Niek Dekker
Principal Scientist, Discovery Biology
AstraZeneca
 
About Speaker:

Professional career 2012-present Principal scientist in Reagents & Assay Development, Discovery Sciences 2008-2012 Delivery Leader to central nervous system and pain (CNS&P) iMed, Cell, Protein & Structural Sciences, Discovery Enabling Capabilities and Sciences, Mölndal, AstraZeneca-R&D, Sweden 2004-2008 Associate Director Protein Engineering Section, Structural Chemistry Laboratories, Mölndal, AstraZeneca-R&D, Sweden 2000-2004 Team Leader Protein Engineering, Structural Chemistry Laboratories-Mölndal, AstraZeneca-R&D, Sweden. 1994-2000 Assistant Professor Utrecht University, the Netherlands. Education 1993 EMBL-funded postdoctoral fellow molecular biology (ETH-Zurich, Switzerland) 1992 postdoctoral fellow NMR spectroscopy (Utrecht University, the Netherlands) 1987-1991 PhD Enzymology (Chemistry faculty, Utrecht University, the Netherlands) 1981-1986 Chemistry Master studies

David Gloriam

David Gloriam
Associate Professor, Drug Design and Pharmacology
University of Copenhagen
David Gloriam
Associate Professor, Drug Design and Pharmacology
University of Copenhagen
 
About Speaker:

David E. Gloriam got his PhD from Uppsala University and after two postdocs at EMBL-EBI and GSK moved to the University of Copenhagen in 2008 where he leads a group for computational drug design. In 2013, he took over the stewardship of the community-driven GPCR database, GPCRdb, expanding the services with e.g. reference data and tools for mutagenesis and crystallisation experiments. In 2014, he received both a ERC Starting Grant and a Lundbeck Foundation Fellowship to identify physiological and tool ligands to characterise orphan receptors. His lab is currently setting up receptor crystallography and a biased agonist resource.

Carsten Hoffman

Carsten Hoffman
Director, Institute of Molecular Cell Biology
University Hospital Jena
Carsten Hoffman
Director, Institute of Molecular Cell Biology
University Hospital Jena
 
About Speaker:

With more than 20 years of experience in GPCR pharmacology and specialized expertise in fluorescence resonance energy transfer approaches (FRET), Prof. Hoffmann´s group is one of the leading academic groups in the development of novel FRET-based sensors for real-time kinetic analyses for GPCR conformational changes in living cells. Since April 2017 Prof. Dr. Carsten Hoffmann is the newly appointed director of the institute for molecular cell biology at the university hospital Jena.

Ali Jazayeri

Ali Jazayeri
CTO
Heptares Therapeutics
Ali Jazayeri
CTO
Heptares Therapeutics
 
About Speaker:

Ali joined Heptares in 2007 and as one of the first scientists he was involved in the transfer of the receptor stabilisation (StaR®) technology from MRC Laboratory of Molecular Biology to Heptares. Following successful implementation and industrialisation of the original technology, he led the development of novel methodologies that significantly increased the efficiency and reach of the StaR® technology. Prior to Heptares, Ali worked as a post-doctoral scientist in Clare Hall Laboratories (a Cancer Research UK institute) and Kudos Pharmaceuticals. In both cases he carried out research on the role of cell cycle checkpoint kinases in DNA damage response pathways. He has a BSc in Genetics from University of Manchester and obtained his PhD in molecular biology with Prof Steve Jackson at the Gurdon Institute from University of Cambridge.

Christoph Klenk

Christoph Klenk
Postdoctoral Fellow, Biochemistry
University of Zurich
Christoph Klenk
Postdoctoral Fellow, Biochemistry
University of Zurich
 
About Speaker:

Christoph Klenk, M.D. Ph.D., is a postdoctoral research fellow at the Department of Biochemistry, University of Zurich. He received a M.D. degree and a Ph.D. degree in molecular pharmacology from University of Würzburg, Germany. Dr. Klenk intensively studied the function of G protein-coupled receptors with a focus on activation and signaling mechanisms of the parathyroid hormone receptor, one of the key targets for osteoporosis therapy. Recently, he joined the lab of Prof. Andreas Plückthun at University of Zurich to investigate the structure-function relationship of G protein-coupled receptor signaling.

Peter Kolb

Peter Kolb
Professor
University of Marburg
Peter Kolb
Professor
University of Marburg
 
About Speaker:

Peter Kolb is a Heisenberg Professor of Pharmaceutical Chemistry at Philipps-University Marburg. He has joind UMR as an Emmy Noether junior group leader in 2011. His research centers on computer-aided ligand discovery. The current focus is on G protein-coupled receptors and method development for fragment-based drug discovery. Prior to his appointment at UMR, he was a postdoctoral fellow at the University of California, San Francisco. Peter holds a Ph.D. in Computational Biochemistry from the University of Zurich and an M.Sc. in Chemistry from the University of Vienna. From 2013-2017, he was chair of COST Action CM1207 "GLISTEN", which united more than 200 GPCR researchers from 31 different countries.

Amadeu Llebaria

Amadeu Llebaria
Director, Medicinal Chemistry & Synthesis
Spanish National Research Council
Amadeu Llebaria
Director, Medicinal Chemistry & Synthesis
Spanish National Research Council
 
About Speaker:

Amadeu Llebaria is head of the MCS group  at IQAC-CSIC Research Institute in Barcelona (Spain). Amadeu is a chemist and has been working in design and synthesis of organic molecules, medicinal chemistry and chemical biology both in basic science and industrial applications. He is now interested in the development of radically new approaches for drug therapeutics. Working in the borderline of chemistry, biology and biophysics he is involved in glycolipid immunotherapeutics, chemical methods for endogenous protein labelling and the use of light for the precise control of protein and receptor activity with photoswitchable ligands.  

Philippe Marin

Philippe Marin
Research Director
CNRS
Philippe Marin
Research Director
CNRS
 
About Speaker:

Philippe Marin completed his PhD in Neuropharmacology in 1992 at the University Pierre and Marie Curie (Paris). He got a permanent position at the CNRS in 1993 to study the mechanisms controlling protein translation in neurons and their role in neurotoxicity at the Laboratory of Neuropharmacology located in Collège de France (Paris). He joined the Institute of Functional Genomics of Montpellier in 1999, where he is the leader of the “Neuroproteomics and Signalling of Neurological and Psychiatric Disorders” team and of the proteomics platform. This team investigates the signalling mechanisms engaged by various serotonergic receptors and their role in the regulation of mood, cognition, pain transmission and neuronal survival, using state-of-the-art proteomics and phosphoproteomics approaches combined with cell biology, electrophysiology and behavioural studies. The team also participates in projects dedicated to biomarker discovery in neurological disorders, including multiple sclerosis and Alzheimer’s disease, thanks to proteomics strategies. P. Marin is the author of 104 publications and two patents (h index = 39).

Kirill Martemyanov

Kirill Martemyanov
Professor, Neuroscience
The Scripps Research Institute
Kirill Martemyanov
Professor, Neuroscience
The Scripps Research Institute
 
About Speaker:

Dr. Martemyanov’s laboratory studies fundamental aspects of neurotransmitter signaling in the nervous system. Over the years his laboratory uncovered and characterized many novel signaling molecules involved in neurotransmission involved in vision, motor control, cognition and actions of addictive drugs. Dr. Martemyanov received his PhD degree in 2000 from the Russian Academy of Sciences. Upon completion of the postdoctoral training at the Harvard Medical School, he joined faculty at the Pharmacology Department at University of Minnesota as a tenure-track Assistant Professor. His laboratory moved to the Scripps Research Institute on Jupiter, FL campus where he became tenured Associate Professor in 2011 and in 2016 was promoted to the rank of Full Professor. Dr. Martemyanov published close to 100 research papers on various aspects of cellular signaling and neuronal communication and his research received many accolades including McKnight Land-Grant Professorship in 2008, Independent Scientist Award from National Institute on Drug Abuse in 2009 and prestigious Cogan Award from the Association for Research in Vision and Ophthalmology in 2014. He directs a productive research group and is well funded for the investigation of the neuronal signaling mechanisms by the National Institutes of Health.

Christel Menet

Christel Menet
Chief Scientific Officer
Confo Therapeutics
Christel Menet
Chief Scientific Officer
Confo Therapeutics
 
About Speaker:

Born in 1975 in France, Christel received an MPhil. in 1999 and a Ph.D. in 2002 both in organic chemistry at the Manchester University, in the UK. During her Ph.D., she was author of 8 publications. She then started her industrial carrier at EvotecOAI, where she developed her expertise in parallel synthesis. Quickly, she joined Faust pharmaceuticals for a new position in 2004, where she did her initiation to medicinal chemistry and neurodegerative diseases, looking for active drugs for mGluRs. She then moved to new challenges at Galapagos. Her carrier at Galapagos was paved with successes including the discovery of 6 active small molecules, which moved to preclinical studies. 3 compounds were tested in phase I clinical trial with a positive proof of mechanism. From these 3, 2 are currently in phase II, GLPG0778 and GLPG0634. The two compounds already showed promising results, Psoriasis for GLPG0778 and RA for GLPG0634. GLPG0634 was the first selective JAK1 inhibitor in clinical trials in inflammatory and auto-immune conditions. She is today CSO of a spin-off company, Confo Therapeutics and she is inventor of more than 20 patents.

Kevin Pfleger

Kevin Pfleger
Head, Molecular Endocrinology & Pharmacology
Harry Perkins Inst. of Medical Research; Uni. of Western Australia
Kevin Pfleger
Head, Molecular Endocrinology & Pharmacology
Harry Perkins Inst. of Medical Research; Uni. of Western Australia
 
About Speaker:

Kevin Pfleger is a National Health and Medical Research Council (NHMRC) RD Wright Fellow and Chief Scientific Advisor of ASX-listed Dimerix Limited. He was awarded his MA and PhD from Cambridge and Edinburgh Universities respectively, and relocated to Australia in 2002. His accolades include NHMRC 10 of the Best Research Projects 2010, Australian Museum Eureka Prize for Emerging Leader in Science 2011, Endocrine Society Early Investigators Award 2012, Endocrine Society of Australia's Mid-Career Research Award 2014, NHMRC Research Excellence Award 2014 for top-ranked fellowship in category and British Pharmacological Society (BPS) Novartis Prize 2016. He is Chair of the Scientific Advisory Committee of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, serves on the International Advisory Group of BPS and is Chair of the Accelerating Australia Executive Committee.

Silvia Sposini

Silvia Sposini
Ph.D. Student
Imperial College London
Silvia Sposini
Ph.D. Student
Imperial College London
 
About Speaker:

Dr. Silvia Sposini recently finished her PhD at Imperial College London, where she has worked in Dr. Aylin Hanyaloglu’s lab investigating the intracellular trafficking and signalling of the Luteinzing hormone receptor. Throughout her academic career she has been focused on GPCRs, looking at different regulatory mechanisms of their activity. Before joining Imperial College, she worked on Prokineticin receptor dimerization at “Sapienza” University of Rome, from  where she obtained both her BSc and MSc degrees (cum laude) in 2010 and 2013, respectively. She has received a number of prizes and scholarships, including the recently awarded Society for Endocrinology Early Career Grant with a project on the effect of allosteric modulators on the spatio-temporal activity of GPCRs.

David Sykes

David Sykes
Scientific Officer
University of Nottingham
David Sykes
Scientific Officer
University of Nottingham
 
About Speaker:

David Sykes has over 20+ years of experience working in a drug discovery environment mainly in a specialist assay development role and most recently with Novartis. During this period David has made a significant contribution to the understanding of agonist/ antagonist GPCR kinetic determinants resulting in a number of high impact publications in an area of growing scientific interest. David is currently employed as an Experimental Officer by The University of Nottingham and studying for a PhD in Molecular Pharmacology and Drug Discovery.. David has recently taken up a new position at the University working in a group led by Prof. Dmitry Veprintsev. His current interests include the development of HTS fluorescence-based kinetic binding assays specifically designed to assess the kinetics of unlabelled compounds and chemical fragments and the use of purified receptor proteins as tools for drug discovery.

Dmitry Veprintsev

Dmitry Veprintsev
Professor of Molecular and Cellular Pharmacology, Centre for Membrane Proteins and Receptors
University of Nottingham
Dmitry Veprintsev
Professor of Molecular and Cellular Pharmacology, Centre for Membrane Proteins and Receptors
University of Nottingham
 
About Speaker:

Dmitry is Professor of Molecular and Cellular Pharmacology in the School of Life Sciences, University of Nottingham. Dmitry did his PhD in biophysics and protein folding at the Russian Academy of Sciences and at the Ohio State University, USA. In 1999, he joined Sir Alan Fersht at the MRC Centre for Protein Engineering and later at the MRC Laboratory of Molecular Biology in Cambridge, UK, first as a Human Frontier postdoctoral fellow and later as a staff scientist. There he focused on the structural and biophysical characterisation of the tumour suppressor p53 and on the development of chemical chaperone strategy to rescue destabilised cancer-associated mutants of p53. In 2010 he became a group leader at the Paul Scherrer Institute in Switzerland where focused his research on the role of protein dynamics in signalling by G protein coupled receptors. He moved to Nottingham in the Autumn 2017.

G protein-coupled receptors (GPCRs), the largest human membrane receptor family, translate extracellular signals, such as changes in the concentrations of hormones and neurotransmitters, into physiological responses by activating one or several intracellular signalling pathways mediated by multiple G proteins and arrestins. His laboratory is interested in structure and dynamics of receptors and their effector molecules and the role of conformations in modulation of signalling. The second focus of his laboratory is on the dynamics of interconnected signalling networks. To link the dynamic behaviour of receptors and effectors with the dynamics of the signalling response, his group aims to develop a proof-of-principle model of cellular signalling by combining experimental and modelling results to characterise the cellular signalling pathways associated with the activation of G protein-coupled receptors. A better understanding of cellular signalling networks will lead to the development of new drugs with reduced side effects, identification of novel drug targets in the signalling networks and development of personalised medicine through deep-signalling pharmacology.

Kinase Inhibitors in Drug Discovery
DISTINGUISHED SPEAKERS
Pedro Beltrao

Pedro Beltrao
Group Leader
EMBL-EBI
Pedro Beltrao
Group Leader
EMBL-EBI
 
About Speaker:

PhD in Biology, University of Aveiro (research conducted at EMBL-Heidelberg), 09/2007. Postdoctoral research at the University of California San Francisco. Group leader at EMBL-EBI since 2013.

Angus Cameron

Angus Cameron
Principal Investigator, Tumour Biology
Barts Cancer Institute
Angus Cameron
Principal Investigator, Tumour Biology
Barts Cancer Institute
 
About Speaker:

I completed my PhD at the University of Glasgow working on immune receptor signal transduction before moving to CRUK London Research Institute to work with Professor Peter Parker on protein kinase C. In 2013 I moved to Barts Cancer Institute to set up my own group, where my interests focus on protein kinase N and mTOR signalling.

Pedro Cutillas

Pedro Cutillas
Reader in Cell Signalling & Protoemics, Barts Cancer Institute
Queen Mary University of London
Pedro Cutillas
Reader in Cell Signalling & Protoemics, Barts Cancer Institute
Queen Mary University of London
 
About Speaker:

Group Leader at Barts Cancer Institute since 2007, Previously at Ludwig Institute, and University College London

Michael Eck

Michael Eck
Professor, Biological Chemistry & Molecular Pharmacology
Harvard Medical School
Michael Eck
Professor, Biological Chemistry & Molecular Pharmacology
Harvard Medical School
 
About Speaker:

Dr. Eck received his M.D. and Ph.D. from the University of Texas Southwestern Medical School and trained as a postdoctoral fellow with Dr. Stephen Harrison at Children’s Hospital and Harvard Medical School before joining the DFCI in 1996. His research focuses on the structure and regulation of tyrosine kinases in cancer and on structure-based approaches to discovery of novel inhibitors.

Jon Elkins

Jon Elkins
Scientific Director, Structural Genomics Consortium
State University of Campinas
Jon Elkins
Scientific Director, Structural Genomics Consortium
State University of Campinas
 
About Speaker:

After a PhD in chemistry from the University of Oxford and post-doctoral work in structural biology of proteins involved in the hypoxic response and in antibiotic biosynthesis, Jon now studies proteins involved in cell signalling and disease, especially protein kinases. Currently Jon is scientific director of the recently established SGC lab in the State University of Campinas (UNICAMP), Brazil. The focus of SGC-UNICAMP is development of chemical probes for protein kinases, to enable new biological insights and target validation.

Amaury Fernández-Montalván

Amaury Fernández-Montalván
Senior Scientist, Lead Discovery Berlin
Bayer AG
Amaury Fernández-Montalván
Senior Scientist, Lead Discovery Berlin
Bayer AG
 
About Speaker:

Amaury Fernández-Montalván is a Senior Research Scientist and Laboratory Head at Bayer Drug Discovery in Berlin. He studied Biochemistry in the University of Havana and obtained his PhD from the Technical University of Munich. Thereafter, he was a postdoctoral researcher at the Novartis Institutes of Biomedical Research in Basel, and Merck Serono International S.A in Geneva. His current responsibilities with Bayer include developing and performing biochemical and biophysical assays for compound identification and profiling in screening, hit-to-lead, and lead optimization campaigns.

Francesco Gervasio

Francesco Gervasio
Professor
University College London
Francesco Gervasio
Professor
University College London
 
About Speaker:

Francesco Luigi Gervasio holds a Chair of biomolecular modelling at University College London where he is Graduate Tutor, professor of Chemistry and professor of Structural and Molecular Biology. He holds a Ph.D. degree in chemistry from the University of Firenze and has been a Postdoc in the group of Michele Parrinello from 2002 to 2006, before becoming Assistant Professor at ETH Zurich and then joining the Spanish National Cancer Research Centre as the leader of the computational biophysics group (2009−2013). He is at UCL as full professor since 2013. He is a member of the Faculty of 1000 and an editor of various journals, including Nature group's Scientific Reports. His research focuses on the development of computer simulations methods and their integration with NMR spectroscopy to understand in details the dynamics of biomolecular systems, with a focus in the activation dynamics of oncogenic kinases.

Stefan Laufer

Stefan Laufer
Chairman Pharm. & Medicinal Chemistry, Department Pharmacy & Biochemistry
University of Tübingen
Stefan Laufer
Chairman Pharm. & Medicinal Chemistry, Department Pharmacy & Biochemistry
University of Tübingen
 
About Speaker:

Chemistry Stefan Laufer, is Professor for Pharmaceutical/Medicinal Chemistry at Tuebingen University. He received his degrees from Regensburg University. After 10 years in Pharmaceutical Industry (Head Drug Research, R&D Director Merckle GmbH) he joined in 1999 Tuebingen University as Chairman Pharm./Med. Chemistry. His research interests are anti-inflammatory and cancer drug discovery with various eicosanoid (COX-1,2,3, LOXs, mPGES1, cPLA2) and protein kinase targets (p38, JAKs, JNKs, CK1d, mtEGRFs) . Three compounds from his lab entered clinical development phases. Dr. Laufer chairs the ICEPHA (Interfaculty Center for Pharmacogenomics and Drug Research) and TüCADD, Tuebingen Center for Academic Drug Discovery. As part of this work, a proprietary kinase inhibitor collections is established (TüKIC, 7000 cpds). He authored more than 380 publications, 15 books/bookchapters and is inventor in 42 patent families.

Daniel Lietha

Daniel Lietha
Group Leader, Cell Signalling and Adhesion Group
Spanish National Cancer Research Centre (CNIO)
Daniel Lietha
Group Leader, Cell Signalling and Adhesion Group
Spanish National Cancer Research Centre (CNIO)
 
About Speaker:

Daniel Lietha received his undergraduate degrees in Chemistry in 1995 and Biotechnology in 1996 from the Zurich University of Applied Sciences (Switzerland). In 1998 he obtained his masters degree in Biotechnology from Teesside University (UK). In 2003 he obtained his PhD degree in Protein Crystallography from Birkbeck College (UK). The research project for his PhD he carried out at the MRC Laboratory of Molecular Biology, Cambridge (UK), under the supervision of E. Gherardi working on Hepatocyte growth factor and its Met receptor. For his postdoctoral training he joined the laboratory of M.J. Eck at the Dana-Faber Cancer Institute, Harvard Medical School, Boston (USA) where he worked on signalling mechanisms involved in cell-matrix adhesion, which led to a seminal contribution on the structure and regulation of Focal Adhesion Kinase. In September 2009 Daniel Lietha joined the CNIO as a Junior Group Leader in the Structural Biology and Biocomputing Programme. In 2011 he was granted a Ramón y Cajal Research Fellowship from the Spanish ministry. His research focuses on the structure and regulation of proteins involved in cellular growth and adhesion signalling. He aims to obtain atomic-level insights into detailed regulatory mechanisms. Further, he utilises structural and mechanistic insights to guide the discovery of small-molecule ligands that target these regulatory mechanisms. Such allosteric compounds are expected to be highly selective for their target.

Henrik Moebitz

Henrik Moebitz
Senior Investigator, Global Discovery Chemistry
Novartis
Henrik Moebitz
Senior Investigator, Global Discovery Chemistry
Novartis
 
About Speaker:

Henrik Möbitz is currently group leader and Senior Research Investigator, Global Discovery Chemistry at Novartis. In this role, he has lead medicinal chemistry projects and external collaborations. Prior to this, he studied enzyme mechanisms by use of biochemistry (PhD at Albert-Ludwigs-Universität Freiburg in 2003) and simulation (Postdoctoral Fellow at UC Santa Barbara). Recent research projects target epigenetic methyl transferases, helicases, kinases and the MAPK pathway in particular, with a focus on integrating structure based design and data analysis.

Matt Robers

Matthew Robers
Senior Research Scientist and Group Leader
Promega
Matthew Robers
Senior Research Scientist and Group Leader
Promega
 
About Speaker:

Matthew Robers is a Senior Research Scientist and Group Leader at Promega Corporation. Matthew received his B.S. Degree in the Dept. of Genetics and his M.S. Degree in the Department of Bacteriology at the University of Wisconsin - Madison. Matthew has authored over 20 peer-reviewed publications and published patents on the application of novel assay chemistries to measure intracellular protein dynamics. Matthew's team currently focuses on the development of new technologies to assess target engagement, and has developed a biophysical technique for quantifying compound affinity and residence time at selected targets within intact cells.

Paul Russell

Paul Russell
Senior Scientist, Therapeutic R&D
Horizon Discovery Ltd
Paul Russell
Senior Scientist, Therapeutic R&D
Horizon Discovery Ltd
 
About Speaker:

Since 2012 Paul Russell has had a Senior Scientist role within Horizon Discovery’s Target Validation and Drug Discovery efforts. He has been using gene manipulation techniques, such as CRISPR & siRNA, to identify & validate synthetic lethal targets associated with common cancer mutations. Prior to this, he spent 18 years in the University of Cambridge; first with Prof Bruce Ponder studying BRCA genetics and then with Prof Ashok Venkitaraman investigating factors that influence the outcome of a drug induced mitotic arrest.

Joshua Salafsky

Joshua Salafsky
Founder and Chief Scientific Officer
Biodesy Inc.
Joshua Salafsky
Founder and Chief Scientific Officer
Biodesy Inc.
 
About Speaker:

Josh is the Founder of Biodesy and the inventor of the Second Harmonic Generation (SHG) technique for studying biological molecules. Josh was awarded a number of NSF and NIH grants and obtained key scientific breakthroughs that galvanized the scientific and venture capital communities.  Previously, Josh was a postdoctoral fellow in the Dept. of Chemistry at Columbia University and the Dept. of Physics at Utrecht University in the Netherlands, as well as a guest researcher at the Cavendish Laboratory at the University of Cambridge, UK. His expertise and interests are in the areas of Biophysics and Physical Chemistry. At Biodesy he leads a team focused on creating novel techniques with SHG and applying them to problems in drug discovery and structural biology.  Josh received his PhD from Stanford University where he studied the reaction center protein, the marvelous engine at the heart of photosynthesis which converts light into chemical energy.

 

Nicolas Soldermann

Nicolas Soldermann
Senior Investigator and Group Leader, Global Discovery Chemistry
Novartis
Nicolas Soldermann
Senior Investigator and Group Leader, Global Discovery Chemistry
Novartis
 
About Speaker:

Nicolas Soldermann studied chemistry at Ecole Nationale Superieure de Chimie de Mulhouse where he obtained his Diplôme d’Ingénieur Chimiste de l’Ecole Nationale Supérieure de Chimie de Mulhouse, France, majoring in medicinal and bioorganic chemistry and a Master in Sciences in organic and macromolecular synthesis from the University of Haute-Alsace, France. He then moved in 1998 to Switzerland to the University of Neuchâtel for a PhD in organic chemistry with Prof. R. Neier. In 2002, he moved to Stanford University in the US for a Postdoc with Prof. P.A. Wender. Nicolas joined Novartis in 2003 in the Global Discovery Chemistry department as an investigator in medicinal chemistry and since then worked in Hit-to-Lead and Lead Optimization project for several diseases areas such as neurosciences, autoimmunity & transplantation and oncology. He led several projects from exploratory to late stage lead optimization yielding several clinical compounds including leniolisib currently in phase 2 for APDS. Nicolas spent about 10 years in the autoimmune and Transplantation field and since 2015 he is a Senior Investigator/Group Leader in Oncology and Immuno-Oncology.

Igor Vivanco

Igor Vivanco
Team Leader
Institute of Cancer Research
Igor Vivanco
Team Leader
Institute of Cancer Research
 
About Speaker:

A native of Peru, Dr Vivanco received his BA in Molecular and Cellular Biology from the University of California at Berkeley, and his PhD in Molecular Biology from the University of California at Los Angeles under Dr. Charles Sawyers. Dr Vivanco completed postdoctoral training in the laboratory of Dr Ingo Mellinghoff at Memorial Sloan Kettering Cancer Center, where he focused on the study of oncogenic EGFR and PI3K signalling. In 2014, he moved to the Institute of Cancer Research in London, where he leads Molecular Addictions team in the Division of Cancer Therapeutics. His laboratory studies the molecular basis of PI3K addiction in a variety of tumours with a particular focus on understanding the contribution of non-catalytic functions of AKT and other AGC kinases to PI3K-dependent cell survival.

Guido Zaman

Guido Zaman
Managing Director & Head of Biology
Netherlands Translational Research Center
Guido Zaman
Managing Director & Head of Biology
Netherlands Translational Research Center
 
About Speaker:

Guido Zaman is Managing Director and Head of Biology of NTRC, a biotech company based in the Netherlands. NTRC (Netherlands Translational Research Center B.V.) translates novel biological concepts into new small molecule drug leads. Guido Zaman founded NTRC together with former colleagues at Merck, Sharp & Dohme (MSD) in 2011. Guido Zaman received his Ph.D. in Science from the University of Nijmegen and worked for five years at the Netherlands Cancer Institute in Amsterdam, before he moved to pharmaceutical industry in 1996. At N.V. Organon, Schering-Plough and MSD he led several multidisciplinary and international teams, including on protein kinases, and was senior director of Molecular Pharmacology.